Cite
MLA Citation
Bethany E. Monteith et al.. “A descriptive cost‐analysis of MYX.1/MCRN003, a phase 2 clinical trial evaluating high‐dose weekly carfilzomib, cyclophosphamide, and dexamethasone in relapsed and refractory multiple myeloma.” European journal of haematology, vol. 107, 2021, pp. 333–342. http://access.bl.uk/ark:/81055/vdc_100136729070.0x000045